Impact of clinical oral chemotherapy program on wastage and hospitalizations

American Journal of Managed Care

Volumn 17, Issue 5, 2011, Pages

  Khandelwal, Nikhil ^a   Duncan, Ian ^a   Ahmed, Tamim ^a   Rubinstein, Elan ^a   Pegus, Cheryl ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHEMOTHERAPY CYCLE MANAGEMENT PROGRAM; CONTROLLED STUDY; DRUG MONITORING; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; MEDICATION THERAPY MANAGEMENT; MEDICATION WASTAGE; PATIENT SATISFACTION; PRIORITY JOURNAL; TREATMENT REFUSAL; TREATMENT WITHDRAWAL;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; COST SAVINGS; HOSPITALIZATION; HUMANS; MEDICAL WASTE; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 79960215237     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. NCCN Drugs and Biologics Compendium by National Comprehensive Cancer Network. http://www.nccn.org/professionals/drug-compendium/content/contents.asp
2. Vanelli M, Pedan A, Liu N, et al: The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther 31:2628-2652, 2009
3. Fitch K, Iwasaki K, Pyenson B: Parity for Oral and Intravenous/Injected Cancer Drugs. Milliman, New York, NY, 2010
4. Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997 (Pubitemid 27021524)
5. Weingart SN, Brown E, Bach PB, et al: NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 6:S1-S14, 2008 (suppl 6) (Pubitemid 351497279)
6. Nexavar (sorafenib) package insert, Bayer Healthcare Pharmaceuticals and Onyx Pharmaceuticals, 2010. http://www.univgraph.com/bayer/inserts/nexavar.pdf
7. Sutent (sunitinib) package insert, Pfizer, 2010. http://www.pfizer.com/ files/products/uspi-sutent.pdf
8. National Cancer Institute: NCI guidelines for investigators: Adverse event reporting requirements for DCTC (CTEP and CIP) and DCP INDS and IDES. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ aeguidelines3-29-11.pdf
9. Tarceva (erlotinib) package insert, Genentech and OSI Oncology, 2010. http://www.gene.com/gene/products/information/pdf/tarceva-prescribing.pdf
10. Wolf MS, Davis TC, Shrank W, et al: To err is human: patient misinterpretations of prescription drug label instructions. Patient Educ Couns 67:293-300, 2007 (Pubitemid 46990725)
11. Ergolin MJ: Promises and pitfalls of oral cancer chemotherapy. Clin Adv Hematol Oncol 7:8-10, 2009
12. Schwartz RN, Eng KJ, Frieze DA, et al: NCCN Task Force Report: Specialty pharmacy. J Natl Compr Canc Netw 8:S1-S12, 2010 (suppl 4)